Novigenix SA is a precision medicine biotechnology company based in Lausanne, Switzerland with a dedicated team of 18 full-time employees and cutting-edge facilities. We specialize in liquid biopsy (LBx) RNA analytics, combining advanced molecular technologies and artificial intelligence to deliver precision immune intelligence that transforms clinical development of novel therapeutics and patient care. Our groundbreaking solution, LITOSeek, is the first AI-enabled Liquid ImmunoTranscriptOmics platform designed for precise and predictive patient profiling. By integrating next-generation sequencing (NGS), artificial intelligence, and a multiomics approach, LITOSeek deciphers systemic immune landscapes using blood RNA biomarkers. This comprehensive analysis incorporates genomics, proteomics, methylation, and transcriptomics to generate robust, patient-specific insights.LITOSeek addresses critical limitations in oncology, where current tumor-centric approaches like ctDNA analysis fail to assess the host immune response or predict clinical benefit accurately. By agnostically analyzing the systemic immune landscape, LITOSeek provides unparalleled predictive power and mechanistic insights into patient responses, far surpassing traditional methods reliant on limited immune cell panels. Validated in metastatic bladder cancer patients undergoing second-line immunotherapy, the platform demonstrated unprecedented predictive capability by consistently identifying all clinical responders, and revealed resistance mechanisms in non-responders. EIC Accelerator support will enable Novigenix to optimize production costs, advance the technology to reduce turnaround time, and broaden market access through a SaaS model targeting biopharma and clinical markets. This support will accelerate LITOSeeks path to mass adoption, unlocking large-scale revenue potential and allowing us to scale rapidly across multiple markets in precision medicine, drug development, and diagnostics.

IMMUcan proposes an inclusive and integrated European immuno-oncology platform. IMMUcan will access high-quality human biological material (tissue, blood, stool and saliva) and clinical data from patients with colorectal, lung, head & neck, breast, gastric cancers and immune checkpoints inhibitors failures. We have assembled a strong consortium with ten expert clinical centers, access to large volumes of the required tumor types. IMMUcan will mobilize the majority of academic trials running or expected to start recruiting patients during the project period. A centralized workflow for samples, via a state-of-the-art biobank will increase reproducibility as all tissues will be processed and stored in a uniform way, following proofed SOPs. The project will perform in depth immunoprofiling with cutting edge technologies including CyTOFF, single cell RNA-seq, peptidogenomics or microbiome analysis. IMMUcan will analyze the data in order to understand the host/tumour interaction in the absence of treatment (naïve population) and with treatment (patients in follow-up) to identify potential predictive biomarker for response to immunotherapy, or develop rationale for combination therapies. IMMUcan will provide an IT platform and legal/ethical contractual framework where participants from both academia and industry can pursue their own independent investigations utilizing the IMMUcan data and effectively testing and improving the functioning and relevance of the database. A sustainability plan will be developed to ensure the collection of follow-up data and the accessibility of the data platform. The use of the data generating throughout this project, for future research, will be supported.